Comparative Survival Associated With Use of Targeted vs Nontargeted Therapy in Medicare Patients With Metastatic Renal Cell Carcinoma.

ABSTRACT:

Importance

Targeted therapies for advanced renal cell carcinoma (RCC) have shown increased tolerability and survival advantages over older treatments in clinical trials, but understanding of real-world survival improvements is still emerging.

Objective

To compare overall and RCC-specific survival associated with use of targeted vs nontargeted therapy for metastatic RCC.

Design, setting, and participants

This retrospective cohort study used Surveillance, Epidemiology, and End Results-Medicare data from 2000 to 2013 to examine patients with stage IV (distant) clear cell RCC at the time of diagnosis who received any targeted or nontargeted therapy. A 2-stage residual inclusion model was fitted to estimate the survival advantages of targeted treatments using an instrument

SUBMITTER: Li P 

PROVIDER: S-EPMC6575152 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature